Research and human subjects.

F. Rivara

DOI: https://doi.org/10.1001/ARCHPEDI.156.7.641

2002-07-01

Abstract:

What problem does this paper attempt to address?

[Non-imported conjunctivitis with detection of Chlamydia trachomatis].

J. Korb,A. Píšová,A. Jirasek,E. Pavlik,K. Melcrová,M. Chválová,H. Mosnová

1989-07-01

Abstract:The authors describe conjunctivitis caused by Chlamydia trachomatis. The diagnosis was established by isolation on tissue cultures with a typical finding of intracytoplasmatic inclusions. Serum antibodies were slightly elevated, the complement binding reaction was 1:16, ELISA 1:64. From the clinical aspect trachoma was not involved. The patient was not in contact with foreigners from endemic areas. The disease was cured only after general administration of Tetracycline. The authors maintain that the diagnosis and prevention of ocular Chlamydia infections in adults and neonates should be extended.
Monitoring Unfractionated Heparin in Adult Patients Undergoing Extracorporeal Membrane Oxygenation (ECMO): ACT, APTT, or ANTI-XA?

Tung Phi Nguyen,Xuan Thi Phan,Dai Quang Huynh,Ha Thi Viet Truong,Yen Nguyen Hai Le,Tuan Manh Nguyen,Quan Quoc Minh Du,Thao Phuong Le,Hai Ngoc Truong,Thi Thi Ho,Thao Thi Ngoc Pham

DOI: https://doi.org/10.1155/2021/5579936

2021-05-03

Critical Care Research and Practice

Abstract:Background. During ECMO, anticoagulants, in particular, unfractionated heparin (UFH), are commonly used and monitored by laboratory tests, including ACT, APTT, and anti-Xa level. Method. A single-center retrospective observational study was conducted on adult patients undergoing ECMO between January 2019 and January 2020 at a tertiary hospital. The correlations between ACT, APTT, anti-Xa, antithrombin, and UFH dose were assessed. Results. 129 sets of measurements from 37 patients were obtained including ACT, APTT, anti-Xa, antithrombin, and UFH dose measured simultaneously. 102 out of 129 sets of values were interpreted as antithrombin deficiencies. The correlation coefficient between APTT and anti-Xa; ACT and anti-Xa are 0.72 and 0.33, respectively, p < 0.001 . The patients with normal antithrombin levels exhibited a significant correlation between APTT and anti-Xa (r = 0.80, p < 0.001 ). ACT, on the other hand, was poorly correlated with UFH dose, whether there is AT deficiency or not. Anti-Xa and APTT are only moderately correlated with UFH dose in the group without antithrombin deficiency, with correlation coefficients of 0.62 and 0.57, respectively, p < 0.05 . Conclusion. APTT value is strongly correlated with anti-Xa value, particularly in patients with normal antithrombin levels. However, the ACT value was poorly correlated with anti-Xa and not with the UFH dose. In groups without antithrombin deficiency, APTT and anti-Xa values only moderately correlated with UFH dose.
A Comparison of Activated Partial Thromboplastin Time and Activated Coagulation Time for Anticoagulation Monitoring during Extracorporeal Membrane Oxygenation Therapy

Ying Liu,Zhiyong Yuan,Xiaoning Han,Kai Song,Jinyan Xing

DOI: https://doi.org/10.1055/a-1796-8652

Abstract:Background: Unfractionated heparin is used to prevent coagulation activation in patients undergoing extracorporeal membrane oxygenation (ECMO) support. We designed this study to determine the preferable indicator for anticoagulation monitoring. Methods: We conducted a retrospective study and divided the patients into an activated coagulation time (ACT)-target group and an activated partial thromboplastin time (aPTT)-target group. The correlations between ACT, aPTT, and the heparin dose were explored. Results: Thirty-six patients were included (19 aPTT-target and 17 ACT-target patients); a total of 555 matched pairs of ACT/aPTT results were obtained. The correlation between the ACT and aPTT measurements was Spearman's Rank Correlation Coefficient (rs) = 0.518 in all 555 pairs. The Bland-Altman plot showed data points outside the displayed range (51.2-127.7), suggesting that the agreement between ACT and aPTT was poor. The aPTT group had fewer heparin dose changes (2.12 ± 0.68 vs. 2.57 ± 0.64, p = 0.05) and a lower cumulative heparin dose (317.6 ± 108.5 vs. 396.3 ± 144.3, p = 0.00) per day than the ACT group. There was no difference in serious bleeding (9 vs. 5; p = 0.171) or embolism events (3 vs. 3; p = 1.0) or in the red blood cell and fresh frozen plasma transfusion volumes between the ACT- and aPTT-target groups. Similarly, there was no significant difference in the ECMO duration (9 [4-15] days vs. 4 [3-14] days; p = 0.124) or length of ICU hospitalization (17 [5-32] days vs. 13 [4-21] days; p = 0.451) between the groups. Conclusion: The correlation between ACT and aPTT and the heparin dose was poor. The aPTT group had fewer daily heparin dose changes and a lower cumulative heparin dose per day than the ACT group, with no more bleeding and thrombotic events. Therefore, we recommend aPTT rather than ACT to adjust heparin dose in the absence of better monitoring indicators.
Evaluation of an aPTT guided versus a multimodal heparin monitoring approach in patients on extra corporeal membrane oxygenation: A retrospective cohort study

Diman Taha,Joppe G Drop,Enno D Wildschut,Matthijs De Hoog,C Heleen van Ommen,Dinis Dos Reis Miranda

DOI: https://doi.org/10.1177/02676591241253474

2024-05-13

Perfusion

Abstract:Introduction: Bleeding and thrombotic complications are common in extracorporeal membrane oxygenation (ECMO) patients and are associated with increased mortality and morbidity. The optimal anticoagulation monitoring protocol in these patients is unknown. This study aims to compare the incidence of thrombotic and hemorrhagic complications before and after a protocol change. In addition, the association between hemostatic complications, coagulation tests and risk factors is evaluated. Methods: This is a retrospective single center cohort study of adult ECMO patients. We collected demographics, ECMO parameters and coagulation test results. Outcomes of the aPTT guided and multimodal protocol, including aPTT, anti-Xa assay and rotational thromboelastometry were compared and the association between coagulation tests, risk factors and hemostatic complications was determined using a logistic regression analysis for repeated measurements. Results: In total, 250 patients were included, 138 in the aPTT protocol and 112 in the multimodal protocol. The incidence of thrombosis (aPTT: 14%; multimodal: 12%) and bleeding (aPTT: 36%; multimodal: 40%), did not significantly differ between protocols. In the aPTT guided protocol, the aPTT was associated with thrombosis (Odds Ratio [OR] 1.015; 95% confidence interval [CI] 1.004-1.027). In both protocols, surgical interventions were risk factors for bleeding and thrombotic complications (aPTT: OR 93.2, CI 39.9-217.6; multimodal OR 17.5, CI 6.5-46.9). Discussion: The incidence of hemostatic complications was similar between both protocols and surgical interventions were a risk factor for hemostatic complications. Results from this study help to elucidate the role of coagulation tests and risk factors in predicting hemostatic complications in patients undergoing ECMO support.
High prevalence of plasmid-mediated quinolone resistance determinant aac(6')-Ib-cr amongst Salmonella enterica serotype Typhimurium isolates from hospitalised paediatric patients with diarrhoea in China.

F. Yu,Qiang Chen,Xiaojun Yu,Jingye Pan,Qiao-qiao Li,Lehe Yang,Congxi Chen,C. Zhuo,Xiaoqiang Li,Xue-qing Zhang,Jinwei Huang,Liangxing Wang

DOI: https://doi.org/10.1016/j.ijantimicag.2010.10.021

IF: 15.441

2011-02-01

International Journal of Antimicrobial Agents

Abstract:
Association of anti‐factor Xa‐guided anticoagulation with hemorrhage during ECMO support: A systematic review and meta‐analysis

Sasa Rajsic,Robert Breitkopf,Benedikt Treml,Dragana Jadzic,Nicole Innerhofer,Christine Eckhardt,Christoph Oberleitner,Zoran Bukumiric

DOI: https://doi.org/10.1002/clc.24273

2024-05-03

Clinical Cardiology

Abstract:There is a moderate correlation between anti‐Xa and the unfractionated heparin dose (UFH) dose, supporting its utilization in monitoring UFH anticoagulation in extracorporeal membrane oxygenation patients. Considering the contemplative limitations of time‐guided monitoring tools, the role of anti‐Xa is promising and further research including recommendations are warranted. Background The use of extracorporeal membrane oxygenation (ECMO) is associated with complex hemostatic changes. Systemic anticoagulation is initiated to prevent clotting in the ECMO system, but this comes with an increased risk of bleeding. Evidence on the use of anti‐Xa‐guided monitoring to prevent bleeding during ECMO support is limited. Therefore, we aimed to analyze the association between anti‐factor Xa‐guided anticoagulation and hemorrhage during ECMO. Methods A systematic review and meta‐analysis was performed (up to August 2023). PROSPERO: CRD42023448888. Results Twenty‐six studies comprising 2293 patients were included in the analysis, with six works being part of the meta‐analysis. The mean anti‐Xa values did not show a significant difference between patients with and without hemorrhage (standardized mean difference −0.05; 95% confidence interval [CI]: −0.19; 0.28, p = .69). We found a positive correlation between anti‐Xa levels and unfractionated heparin dose (UFH; pooled estimate of correlation coefficients 0.44; 95% CI: 0.33; 0.55, p

cardiac & cardiovascular systems
Whole-blood Point-of-Care Activated Partial Thromboplastin Time Ratio (APR) is not Accurate Enough to Monitor Heparin Therapy in Patients with Severe Respiratory Failure Secondary to SARS-Cov-2 Infection Supported with Veno-Venous Extracorporeal Membrane Oxygenation (VV-ECMO)

Daniel Aston,Martin Besser,Ben Goddard,Nicholas Maggs,Hassan Ahmed,Florian Falter

DOI: https://doi.org/10.1177/10760296221148162

Abstract:Support with VV-ECMO requires anticoagulation with unfractionated heparin to prevent thrombotic complications. This must be monitored due to bleeding risk. A point-of-care (POC) method of testing aPTT and APR was evaluated for agreement with laboratory methods. In a prospective observational study, patients supported on VV-ECMO as a result of severe respiratory failure secondary to Covid-19 infection were given heparin as part of standard therapy. The aPTT was measured (i) at the bedside using the Hemochron Signature Elite device and (ii) at the hospital laboratory. Duplicate results were compared. Agreement between the POC and laboratory tests was poor, as assessed using the Bland-Altman method. The maximum difference between POC and laboratory methods was 133% and the minimum was 0%. Overall bias was 7.3% and limits of agreement were between -43.8% and 58.5%. Correlation increased when results were normalised to platelet count and creatinine. This POC test is insufficiently accurate for use as the primary method of heparin monitoring in patients requiring VV-ECMO for Covid-19. Platelets and renal function may influence the result of this whole blood POC test.
Discordance among assays for monitoring? Anticoagulation during extracorporeal life support

Erik J Scott,Evan Rotar,Jolian J Dahl,Jared P Beller,Dustin T Money,W Z Chancellor,J H Mehaffey,Matt Morisette,Leora T Yarboro,Nicholas R Teman

DOI: https://doi.org/10.1177/02676591221129741

Perfusion

Abstract:Objectives: The optimal method for monitoring of anticoagulation in patients on extracorporeal life support (ECLS) is unknown. The objective of this study was to assess the relationship between anti-factor Xa level (anti-Xa; IU/mL) and activated partial thromboplastin time (aPTT; seconds) for monitoring intravenous unfractionated heparin anticoagulation in adult ECLS patients. Methods: Charts of all adult patients cannulated for ECLS from 2015 through 2017 were reviewed and laboratory and heparin infusion data were extracted for analysis. Time matched pairs of anti-Xa and aPTT were considered concordant if both laboratory values were within the same clinically utilized range. A hierarchical logistic regression model was used to determine factors associated with discordance while accounting for patient level effects. Results: A total of 1016 paired anti-Xa and aPTT values from 65 patients were evaluated. 500 (49.2%) paired samples were discordant with a degree of variability on linear regression (r2 = 0.315). The aPTT fell into a higher therapeutic range compared to the anti-Xa in 31.6% and lower in 17.3%. Logistic regression demonstrated that discordance was independently associated with time from initiation of ECLS (OR 1.17 per day, p < 0.001), average heparin infusion rate (OR 1.25 per U/kg/hr, p < 0.001), and INR (OR 3.22, p < 0.001). Conclusions: Nearly half of all aPTT and anti-Xa values were in discordant ranges and discordance is more likely as the time on ECLS and the INR level increase. The use of either assay in isolation to guide heparin anticoagulation may lead to misestimation of the degree of anticoagulation in complex ECLS patients.
Parameter estimation of hydrologic models using a likelihood function for censored and binary observations.

O. Wani,A. Scheidegger,J. P. Carbajal,J. Rieckermann,F. Blumensaat

DOI: https://doi.org/10.1016/j.watres.2017.05.038

IF: 12.8

2017-09-15

Water Research

Abstract:
Anti-Xa-guided anticoagulation with unfractionated heparin and thrombosis during ECMO support: A systematic review and meta-analysis

Rajsic Sasa,Breitkopf Robert,Treml Benedikt,Jadzic Dragana,Innerhofer Nicole,Eckhardt Christine,Oberleitner Christoph,Nawabi Fariha,Bukumiric Zoran

DOI: https://doi.org/10.1053/j.jvca.2024.03.042

IF: 2.894

2024-04-04

Journal of Cardiothoracic and Vascular Anesthesia

Abstract:Objective The initiation of extracorporeal life support (ECMO) triggers complex coagulation processes, necessitating systemic anticoagulation. Therefore, anticoagulation monitoring is crucial to avoid adverse events such as thrombosis and haemorrhage. The main aim of this work is to analyse the association between anti-Xa levels and thrombosis occurrence during ECMO support. Design Systematic literature review and meta-analysis (Scopus and PubMed, up to July 29, 2023) Setting All retrospective and prospective studies Participants Patients receiving ECMO support Intervention Anticoagulation monitoring during ECMO support Measurements and main results We included 16 articles with 1968 patients in the review and 7 studies in the meta-analysis (n = 374). Patients with thrombosis had significantly lower mean anti-Xa values (SMD -0.36; 95%CI -0.62; -0.11, p <0.01). Furthermore, we observed a positive correlation between unfractionated heparin infusion and anti-Xa levels (pooled estimate of correlation coefficients 0.31; 95% CI 0.19; 0.43, p < 0.001). The most common adverse events were major bleeding (42%) and any kind of haemorrhage (36%), followed by thromboembolic events (30%) and circuit or oxygenator membrane thrombosis (19%). More than half of the patients did not survive until discharge (52%). Conclusions Our work revealed significantly lower levels of anti-Xa in patients experiencing thromboembolic events, and a positive correlation between anti-Xa and unfractionated heparin infusion. Considering the contemplative limitations of conventional monitoring tools, further research on the role of anti-Xa is warranted. New trials should be encouraged to confirm our findings and determine the most suitable monitoring strategy for patients receiving ECMO support.

cardiac & cardiovascular systems,peripheral vascular disease,respiratory system,anesthesiology
Association of aPTT-Guided Anticoagulation Monitoring with Thromboembolic Events in Patients Receiving V-A ECMO Support: A Systematic Review and Meta-Analysis

Sasa Rajsic,Robert Breitkopf,Benedikt Treml,Dragana Jadzic,Christoph Oberleitner,Ulvi Cenk Oezpeker,Nicole Innerhofer,Zoran Bukumiric

DOI: https://doi.org/10.3390/jcm12093224

2023-04-30

Abstract:Background: The initiation of extracorporeal membrane oxygenation (ECMO) is associated with complex inflammatory and coagulatory processes, raising the need for systemic anticoagulation. The balance of anticoagulatory and procoagulant factors is essential, as therapeutic anticoagulation confers a further risk of potentially life-threatening bleeding. Therefore, our study aims to systematize and analyze the most recent evidence regarding anticoagulation monitoring and the thromboembolic events in patients receiving veno-arterial ECMO support. Methods: Using the PRISMA guidelines, we systematically searched the Scopus and PubMed databases up to October 2022. A weighted effects model was employed for the meta-analytic portion of the study. Results: Six studies comprising 1728 patients were included in the final analysis. Unfractionated heparin was used for anticoagulation, with an activated partial thromboplastin time (aPTT) monitoring goal set between 45 and 80 s. The majority of studies aimed to investigate the incidence of adverse events and potential risk factors for thromboembolic and bleeding events. None of the authors found any association of aPTT levels with the occurrence of thromboembolic events. Finally, the most frequent adverse events were hemorrhage (pooled 43%, 95% CI 28.4; 59.5) and any kind of thrombosis (pooled 36%, 95% CI 21.7; 53.7), and more than one-half of patients did not survive to discharge (pooled 54%). Conclusions: Despite the tremendous development of critical care, aPTT-guided systemic anticoagulation is still the standard monitoring tool. We did not find any association of aPTT levels with thrombosis. Further evidence and new trials should clarify the true incidence of thromboembolic events, along with the best anticoagulation and monitoring strategy in veno-arterial ECMO patients.
Anticoagulation Monitoring Using Activated Clotting Time in Patients Receiving Extracorporeal Membrane Oxygenation: A Meta-Analysis of Correlation Coefficients

Sasa Rajsic,Daniel Schwaiger,Lukas Schausberger,Robert Breitkopf,Benedikt Treml,Dragana Jadzic,Christoph Oberleitner,Zoran Bukumiric

DOI: https://doi.org/10.1053/j.jvca.2024.07.048

2024-08-05

Abstract:Objective: Extracorporeal membrane oxygenation (ECMO) requires systemic anticoagulation to maintain the circuit patency. However, the use of anticoagulation carries a risk of severe hemorrhage, necessitating rigorous monitoring. Activated clotting time (ACT) is a widely used monitoring tool; however, the evidence of its correlation with unfractionated heparin (UFH) infusion dose is limited. Here we aimed to analyze the correlation between ACT and UFH infusion during ECMO. Design: Systematic literature review and meta-analysis of correlation coefficients (Scopus and PubMed, up to July 13, 2024). Prospero: CRD42023448888 SETTING: All retrospective and prospective studies PARTICIPANTS: Patients receiving ECMO support INTERVENTION: Anticoagulation monitoring during ECMO support MEASUREMENTS AND MAIN RESULTS: Nineteen studies were included in the analysis, and the meta-analysis encompassed 16 studies. The vast majority of studies (n = 15) found a weak correlation, and no study reported a strong correlation between ACT and UFH infusion dose. The meta-analysis (n = 12,625 samples) identified a weak correlation, with a pooled estimate of correlation coefficients of 0.132 (95% confidence interval 0.03-0.23). The most common adverse events were hemorrhage (pooled incidence, 45%) and thrombosis (30%), and 47% of the patients died during their hospital stay. Conclusions: Even though ACT is a widely used UFH monitoring tool in ECMO patients, our meta-analysis found a weak correlation between ACT and UFH infusion dose. New trials are needed to investigate the role of emerging tools and to clarify the most appropriate monitoring strategy for patients receiving ECMO support.
Antimicrobial therapy of experimental intraabdominal sepsis.

William M. Weinstein,Andrew B. Onderdonk,John G. Bartlett,Thomas J. Louie,Sherwood L. Gorbach

DOI: https://doi.org/10.1093/INFDIS/132.3.282

1975-09-01

Abstract:Septic complications of colonic perforation involve miltiple bacteria derived from the intestinal flora. This type of mixed intraabdominal infection was produced experimentally by insertion of a standardized inoculum of rat colonic contents into the peritoneal cavity of male Wistar rats. The respective roles of coliforms and anerobic bacteria were then studied by use of selective antimicrobial therapy (with gentamicin and clindamycin). Untreated rats had a two-stage disease. Initally, there was an acute peritonitis associated with a 37% mortality rate; all animals that survived developed indolent intraabdominal abscesses. Treatment with gentamicin reduced the acute mortality rate to 4%, but 98% of the survivors had abscesses. Clindamycin acute mortalherapy was associated with a 35% mortality rate, but the incidence of intraabdominal abscess was only 5%. A combination of gentamicin and clindamycin yielded the salutary effects of each agent--7% mortality and 6% incidence of abscesses. These studies, in concert with bacteriological findings, suggest that coliforms caused early mortality while anaerobes were primarily responsible for the late complication of intraabdominal abscess formation.
Outcomes of heparinized adult veno-arterial extracorporeal membrane oxygenation patients managed with low and high activated partial thromboplastin time targets: A systematic review and meta-analysis

Michael Mazzeffi,Dora Lin,Alberto Gonzalez-Almada,D Keegan Stombaugh,Jonathan Curley,Venkat Mangunta,Nicholas Teman,Leora T Yarboro,Robert Thiele

DOI: https://doi.org/10.1177/02676591221150880

2023-01-05

Perfusion

Abstract:Perfusion, Ahead of Print. IntroductionThere are no randomized controlled trials comparing low and high activated partial thromboplastin time (aPTT) targets in heparinized adult veno-arterial (VA) extracorporeal membrane oxygenation (ECMO) patients. Our systematic review and meta-analysis summarized complication rates in adult VA ECMO patients treated with low and high aPTT targets.MethodsStudies published from January 2000 to May 2022 were identified using Pubmed, Embase, Cochrane Library, and LILACS (Latin American and Caribbean Health Sciences Literature). Studies were included if aPTT was primarily used to guide heparin anticoagulation. For the low aPTT group, we included studies where aPTT goal was ≤60 seconds and for the high aPTT group, we included studies where aPTT goal was ≥60 seconds. Proportional meta-analysis with a random effects model was used to calculate pooled complication rates for patients in the two aPTT groups.ResultsTwelve studies met inclusion criteria (5 in the low aPTT group and 7 in the high aPTT group). The pooled bleeding complication incidence for low aPTT studies was 53.6% (95% CI = 37.4%–69.4%, I2 = 60.8%) and for high aPTT studies was 43.8% (95% CI = 21.7%–67.1%, I2 = 91.8%). No studies in the low aPTT group reported overall thrombosis incidence, while three studies in the high aPTT group reported overall thrombosis incidence. The pooled thrombosis incidence for high aPTT studies was 16.1% (95% CI = 9.0%–24.5%, I2 = 13.1%).ConclusionsAdult ECMO patients managed with low and high aPTT goals appeared to have similar bleeding and other complication rates further highlighting the need for a randomized controlled trial.
Hemostasis During Extracorporeal Membrane Oxygenation: More Questions

Lin Chen,Zhongheng Zhang,Kun Chen

DOI: https://doi.org/10.1016/j.healun.2020.08.011

2020-01-01

Abstract:We read the study by Durila et al 1 Durila M, Vajter J, Garaj M, et al. Acquired primary hemostasis pathology detected by platelet function analyzer 200 seen during extracorporeal membrane oxygenation is sufficient to prevent circuit thrombosis: a pilot study. J Heart Lung Transplant. 2020;39:980-982. Google Scholar with interest; however, we seek several clarifications. First, a separate study by Yu et al 2 Yu ES, Jeon MJ, Kang KW, et al. The role of platelet function analyzer-200 in predicting perioperative bleeding risk [e-pub ahead of print]. Korean J Intern Med. doi:10.3904/kjim.2019.112, accessed September 9, 2020. Google Scholar showed that the results of platelet function analyzer 200 (PFA 200) are influenced by various factors, such as the use of aspirin and other non-steroidal anti-inflammatory agents, blood group type, hematocrit and time of blood collection, transfusions, and underlying diseases. The severity of surgery might cause bleeding, which affects collagen–epinephrine and collagen–adenosine diphosphate. The conclusion that the pathology of primary hemostasis detected by the PFA 200 (collagen–epinephrine and collagen–adenosine diphosphate) was specific for the extracorporeal membrane oxygenation (ECMO) phase of surgery is not robust and is subject to confounding bias. 3 Zhang Z Model building strategy for logistic regression: purposeful selection. Ann Transl Med. 2016; 4: 111 Crossref PubMed Scopus (192) Google Scholar Second, a continuous intravenous infusion of low-molecular-weight heparin was used to prevent venous thromboprophylaxis, but without dose described. Piwowarczyk et al 4 Piwowarczyk P, Borys M, Kutnik P, et al. Unfractionated heparin versus subcutaneous nadroparin in adults supported with venovenous extracorporeal membrane oxygenation: a retrospective, multicenter study [e-pub ahead of print]. ASAIO J. doi:10.1097/MAT.0000000000001166, accessed September 9, 2020. Google Scholar compared nadroparin with unfractionated heparin during veno-venous ECMO and found no significant difference in the number of thrombotic and hemorrhagic events. In the paper by Durila et al, 1 Durila M, Vajter J, Garaj M, et al. Acquired primary hemostasis pathology detected by platelet function analyzer 200 seen during extracorporeal membrane oxygenation is sufficient to prevent circuit thrombosis: a pilot study. J Heart Lung Transplant. 2020;39:980-982. Google Scholar even with the use of continuous intravenous infusion of low-molecular-weight heparin, 2 patients suffered thrombotic events. Third, the duration of the ECMO in their work is short (5 ± 3 days). The effect of duration of support on outcomes was not provided because we would suggest that the risk of thrombotic events is lower with a shorter duration of ECMO support. Given these considerations, it is difficult for us to completely agree with the conclusion that the PFA 200 analyzer may be used to prevent circuit thrombosis instead of using unfractionated heparin in patients on prolonged ECMO. We believe that a point-of-care test such as the PFA 200 may assist in adjusting anti-coagulant strategy to potentially reduce the use of unfractionated heparin rather than to prevent circuit thrombosis and obviate the use of unfractionated heparin altogether, especially in patients on prolonged ECMO support.
Discordance between aPTT and anti‐Xa in monitoring heparin anticoagulation in mechanical circulatory support

Song Li,Ang Li,Jennifer A. Beckman,Christopher Kim,Marian A. Granich,John Mondin,Daniel E. Sabath,David A. Garcia,Claudius Mahr

DOI: https://doi.org/10.1002/ehf2.14816

2024-05-11

ESC Heart Failure

Abstract:Aims It is unclear whether activated partial thromboplastin time (aPTT) or anti‐Xa is more accurate for monitoring heparin anticoagulation in mechanical circulatory support (MCS) patients. This study investigates the relationship between aPTT and anti‐Xa in MCS patients and identifies predictors of discordance. Methods and results aPTT and anti‐Xa were simultaneously measured in a prospective cohort of MCS patients receiving unfractionated heparin at a tertiary academic medical centre. Therapeutic aPTT and anti‐Xa levels were 60–100 s and 0.3–0.7 IU/mL, respectively, and concordance was defined as both levels being subtherapeutic, therapeutic, or supratherapeutic. To identify predictors of discordance, both a machine learning random forest model and a multivariate regression model were applied to patient demographics, device type, and 14 laboratory variables; 23 001 pairs of simultaneously measured aPTT/anti‐Xa were collected from 699 MCS patients. aPTT and anti‐Xa were concordant in 35.5% of paired observations and discordant in 64.5% (aPTT > antiXa 61.5%; aPTT antiXa) was associated with high INR, eGFR, and total bilirubin, as well as low platelets, haemoglobin, pre‐albumin, white blood cell count, and haptoglobin. Total artificial heart and durable ventricular assist devices were more likely to be associated with aPTT > anti‐Xa than temporary MCS devices. Conclusions aPTT and anti‐Xa were frequently discordant in MCS patients receiving heparin anticoagulation. Clinical conditions common in MCS patients such as concurrent warfarin use, malnutrition, haemolysis, and thrombocytopenia, as well as durable type of MCS devices were associated with a high aPTT relative to anti‐Xa.

cardiac & cardiovascular systems
Effects of neem (Azadirachta indica) extracts onLeptocorisa chinensis under choice and no-choice conditions

D. Ma,Yoshito Suzuki,H. Takeuchi,Tomonari Watanabe,M. Ishizaki

DOI: https://doi.org/10.1007/BF02981400

IF: 1.809

2005-10-01

Phytoparasitica

Abstract:
Evaluation of a Multimodal Heparin Laboratory Monitoring Protocol in Adult Extracorporeal Membrane Oxygenation Patients

Kalynn A. Northam,Bobbie Nguyen,Sheh-Li Chen,Edward Sredzienski,Anthony Charles

DOI: https://doi.org/10.1177/08971900211021249

2021-06-10

Journal of Pharmacy Practice

Abstract:Background: Anticoagulation monitoring practices vary during extracorporeal membrane oxygenation (ECMO). The Extracorporeal Life Support Organization describes that a multimodal approach is needed to overcome assay limitations and minimize complications. Objective: Compare activated clotting time (ACT) versus multimodal approach (activated partial thromboplastin time (aPTT)/anti-factor Xa) for unfractionated heparin (UFH) monitoring in adult ECMO patients. Methods: We conducted a single-center retrospective pre- (ACT) versus post-implementation (multimodal approach) study. The incidence of major bleeding and thrombosis, blood product and antithrombin III (ATIII) administration, and UFH infusion rates were compared. Results: Incidence of major bleeding (69.2% versus 62.2%, p = 0.345) and thrombosis (23% versus 14.9%, p = 0.369) was similar between groups. Median number of ATIII doses was reduced in the multimodal group (1.0 [IQR 0.0-2.0] versus 0.0 [0.0 -1.0], p = 0.007). The median UFH infusion rate was higher in the ACT group, but not significant (16.9 [IQR 9.6-22.4] versus 13 [IQR 9.6-15.4] units/kg/hr, p = 0.063). Fewer UFH infusion rate changes occurred prior to steady state in the multimodal group (0.9 [IQR 0.3 -1.7] versus 0.1 [IQR 0.0-0.2], p < 0.001). Conclusion: The incidence of major bleeding and thrombosis was similar between groups. Our multimodal monitoring protocol standardized UFH infusion administration and reduced ATIII administration.
Antithrombin during veno-venous extracorporeal membrane oxygenation with heparin anticoagulation: A single-center cohort study

Bethany A Hileman,Gennaro Martucci,Nicolò Rizzitello,Giovanna Occhipinti,Matteo Rossetti,Fabio Tuzzolino,Roberto Lorusso,Mauro Panigada,Kenichi Tanaka,Antonio Arcadipane,Giovanna Panarello

DOI: https://doi.org/10.1177/02676591241258048

2024-06-06

Perfusion

Abstract:Perfusion, Ahead of Print. IntroductionAntithrombin (AT) is a natural anticoagulant essential to enhancing the unfractionated heparin (UFH) anticoagulant effect. Its supplementation in the management of UFH-based anticoagulation during veno-venous extracorporeal membrane oxygenation (VV ECMO) has a strong pathophysiological rationale.MethodsThis is a single-center, retrospective cohort study of adult VV ECMO patients with anticoagulation maintained by UFH targeting an activated partial thromboplastin time (aPTT) of 40–50 s and AT activity >80%. We compare anticoagulation management and survival outcomes between AT subpopulations, defined by a threshold AT activity ≥80%. Linear and logistic regression analyses were used to evaluate the variation in AT activity and its association with ICU survival.ResultsIn 244 patients enrolled from 2009 to 2022, anticoagulation was maintained by a median heparin dose of 11.4 IU/kg/h [IQR: 8.2–14.7] with a mean aPTT of 46.1 s (±7.3) and AT activity of 88.9% (±17.0). A lower mean aPTT, higher dose of UFH and shorter fraction of time without UFH were associated with higher AT activity (p < .01). Higher AT activity showed a consistent association with ICU survival (for 10% increase of AT, odds ratio for ICU mortality: 0.95; 95% CI 0.93–0.97; p value <.01).ConclusionsThere is a positive association between AT activity and UFH requirements but no significant difference in the rate of bleeding events. A higher mean AT during VV ECMO was associated with ICU survival. Future studies are needed to differentiate between exogenously supplemented versus endogenous AT effect.

cardiac & cardiovascular systems,peripheral vascular disease
Prevalence of FXII-Deficiency and Its Relevance to Monitoring Anticoagulation in Adults Receiving Extracorporeal Membrane Oxygenation

Roman Brock,Andrea Kornfehl,Thomas Staudinger,Peter Schellongowski,Peter Quehenberger,Michael Schwameis,Nina Buchtele

DOI: https://doi.org/10.1097/MAT.0000000000002085

2024-03-01

Abstract:During extracorporeal membrane oxygenation (ECMO) blood is exposed to artificial surfaces, resulting in contact activation of the intrinsic coagulation pathway initiated by coagulation factor XII (FXII). Little is known about the prevalence of acquired FXII-deficiency, especially during ECMO. The primary outcome was the prevalence of acquired FXII-deficiency (FXII activity <60%) during ECMO. Secondary outcomes included differences in hemorrhagic/thromboembolic complications, doses of unfractionated heparin administered, and time points of anticoagulation within target ranges between patients with and without FXII-deficiency. Of 193 adults receiving ECMO therapy between 2013 and 2021, FXII testing was performed in 64 (33%) patients. Of these, 89% ( n = 57) had an acquired FXII-deficiency. Median complication-free intervals were not different between patients with and without acquired FXII-deficiency (bleeding: 28 days [6-145] vs. 12 days [11-not available], p = 0.85; thromboembolism: 16 days [8-54] vs. 13 days [3-15], p = 0.053). Patients with acquired FXII-deficiency received less heparin (16,554 IU/day vs. 25,839 IU/day; p = 0.009) and were less likely to be within aPTT-target ranges (23.1% [14.3%-36.4%] vs. 37.8% [33.7%-58.3%], p = 0.005). Acquired FXII-deficiency is common during ECMO and may affect monitoring of anticoagulation. The impact of FXII-activity on complications needs to be determined in future studies.

Research and human subjects.

[Non-imported conjunctivitis with detection of Chlamydia trachomatis].

Monitoring Unfractionated Heparin in Adult Patients Undergoing Extracorporeal Membrane Oxygenation (ECMO): ACT, APTT, or ANTI-XA?

A Comparison of Activated Partial Thromboplastin Time and Activated Coagulation Time for Anticoagulation Monitoring during Extracorporeal Membrane Oxygenation Therapy

Evaluation of an aPTT guided versus a multimodal heparin monitoring approach in patients on extra corporeal membrane oxygenation: A retrospective cohort study

High prevalence of plasmid-mediated quinolone resistance determinant aac(6')-Ib-cr amongst Salmonella enterica serotype Typhimurium isolates from hospitalised paediatric patients with diarrhoea in China.

Association of anti‐factor Xa‐guided anticoagulation with hemorrhage during ECMO support: A systematic review and meta‐analysis

Whole-blood Point-of-Care Activated Partial Thromboplastin Time Ratio (APR) is not Accurate Enough to Monitor Heparin Therapy in Patients with Severe Respiratory Failure Secondary to SARS-Cov-2 Infection Supported with Veno-Venous Extracorporeal Membrane Oxygenation (VV-ECMO)

Discordance among assays for monitoring? Anticoagulation during extracorporeal life support

Parameter estimation of hydrologic models using a likelihood function for censored and binary observations.

Anti-Xa-guided anticoagulation with unfractionated heparin and thrombosis during ECMO support: A systematic review and meta-analysis

Association of aPTT-Guided Anticoagulation Monitoring with Thromboembolic Events in Patients Receiving V-A ECMO Support: A Systematic Review and Meta-Analysis

Anticoagulation Monitoring Using Activated Clotting Time in Patients Receiving Extracorporeal Membrane Oxygenation: A Meta-Analysis of Correlation Coefficients

Antimicrobial therapy of experimental intraabdominal sepsis.

Outcomes of heparinized adult veno-arterial extracorporeal membrane oxygenation patients managed with low and high activated partial thromboplastin time targets: A systematic review and meta-analysis

Hemostasis During Extracorporeal Membrane Oxygenation: More Questions

Discordance between aPTT and anti‐Xa in monitoring heparin anticoagulation in mechanical circulatory support

Effects of neem (Azadirachta indica) extracts onLeptocorisa chinensis under choice and no-choice conditions

Evaluation of a Multimodal Heparin Laboratory Monitoring Protocol in Adult Extracorporeal Membrane Oxygenation Patients

Antithrombin during veno-venous extracorporeal membrane oxygenation with heparin anticoagulation: A single-center cohort study

Prevalence of FXII-Deficiency and Its Relevance to Monitoring Anticoagulation in Adults Receiving Extracorporeal Membrane Oxygenation